Crinetics Pharmaceuticals
Manufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
6055 Lusk Blvd, San Diego, California, 9...Phone Number
(858) 450-6464Website
www.crinetics.comRevenue
$18.1 MillionStock Symbol
CRNXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
2
1
1
About Crinetics Pharmaceuticals
Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. Were here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure were solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.Explore more
Crinetics Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Crinetics Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Crinetics Pharmaceuticals launches new products
Earning: See what the market has to say on Crinetics Pharmaceuticals recently announced quarterly report
Crinetics Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Crinetics Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Crinetics Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Crinetics Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Crinetics Pharmaceuticals has new funding data
Check if Crinetics Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Crinetics Pharmaceuticals
Find more new buyers
Compare Similar Companies to Crinetics Pharmaceuticals
Compare insights from companies similar to Crinetics Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Crinetics Pharmaceuticals
$18.1M
501-1,000
Public
$100M
2008
NL
Niccole LeChief of Staff To the Chief Operating Officer and Head of Alliance Management
Company Profile Activity
Activity Insights
Crinetics Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Crinetics Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals financials insights
Gather financial insights about Crinetics Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$100M
Crinetics Pharmaceuticals Tech Stack
A closer look at the technologies used by Crinetics Pharmaceuticals
See more technologies
Most Recent Scoops
Open Position
Earnings
Crinetics Pharmaceuticals has reported that the combined peak sales potential of paltusotine and atumelnant is expected to exceed $5 billion in annual revenue, with the Crinetics acquisition anticipated to be accretive to non-GAAP operating income in 2029 and margin accretive over time, while the impact to 2026 revenue and non-GAAP operating expenses is expected to be modest given the anticipated Q3 2026 closing.
Project
Crinetics Pharmaceuticals is advancing atumelnant, a once-daily oral ACTH receptor antagonist, in Phase III development for congenital adrenal hyperplasia (CAH) and Phase II development for ACTH-dependent Cushing's syndrome, with multi-billion dollar peak sales potential seen across both indications.
Pharmaceuticals
Earnings
Crinetics Pharmaceuticals has reported net product revenue of $10.3 million for paltusotine in Q1 2026, with the product achieving a 40% to 50% share of new-to-brand prescriptions in its second quarter of launch, reflecting broad uptake across pituitary centers, community endocrinologists, and all patient segments including injectable SRL switch, treatment-naive, and patients who had discontinued therapy.
Earnings, Product Launch, Finance
Project
Crinetics Pharmaceuticals News & Media
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
BALA CYNWYD, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
BALA CYNWYD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
Vertex Pharmaceuticals recently announced its largest-ever acquisition.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Crinetics Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. Were here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure were solving real problems for them. And we build value in... Read More
